Protein-protein interactions were measured for ovalbumin and for lysozyme in aqueous salt solutions. Protein-protein interactions are correlated with a proposed potential of mean force equal to the free energy to desolvate the protein surface that is made inaccessible to the solvent due to the protein-protein interaction. This energy is calculated from the surface free energy of the protein that is determined from protein-salt preferential-interaction parameter measurements. In classical salting-out behavior, the protein-salt preferential interaction is unfavorable. Because addition of salt raises the surface free energy of the protein according to the surface-tension increment of the salt, protein-protein attraction increases, leading to a reduction in solubility. When the surface chemistry of proteins is altered by binding of a specific ion, salting-in is observed when the interactions between (kosmotrope) ion-protein complexes are more repulsive than those between the uncomplexed proteins. However, salting-out is observed when interactions between (chaotrope) ion-protein complexes are more attractive than those of the uncomplexed proteins.
A simple, relatively low-cost direct injection high-efficiency nebulizer (DIHEN) is introduced for argon inductively coupled plasma (Ar ICP) spectrometry. The DIHEN may be operated at solution uptake rates of 1-100 microL/min. Analytical performance indexes for the DIHEN and fundamental characteristics of the aerosol produced are obtained using an ICP mass spectrometer (ICPMS) and a two-dimensional phase Doppler particle analyzer (2D PDPA), respectively. Results are compared to those obtained with a conventional crossflow pneumatic nebulizer (PN), equipped with a Scott-type spray chamber. Droplet sizes and velocities produced with the DIHEN are smaller than those reported for the direct injection nebulizer (DIN). The DIHEN offers optimal sensitivity at low injector gas flow rates (approximately 0.25 L/min) and high rf power (approximately 1.5 kW). For the 17 elements tested, detection limits (ppt) and sensitivities achieved with the DIHEN (at 85 microL/min) are similar to, or better than, those obtained on the same instrument using the PN (at 1 mL/min). However, because the primary aerosol is injected directly into the plasma, oxide-to-metal ion ratios (MO+/M+) are high, as in the case of the DIN. The utility of the DIHEN for the analysis of small-volume samples is demonstrated by microscale flow injection analysis (muFIA) of Cr bound to human lung DNA. Detection of Cr at the femtogram level is feasible.
A large bore-direct injection high efficiency nebulizer (IB-DIHEN) is introduced that is less prone to capillary blockage and optimally operates at low nebulizer gas pressures compared with the conventional DIHEN used for inductively coupled plasma (ICP) spectrometries. The aerosol quality is examined using a two-dimensional phase Doppler particle analyzer (2D PDPA), and analytical figures of merits are acquired by ICP mass spectrometry. Compared with the DIHEN, the LB-DIHEN produces larger droplets, but the velocity distributions and mean droplet velocities are narrower and lower, respectively, providing longer residence times for the droplets in the plasma. High RF power (1500 W), low nebulizer gas flow rates (0.25-0.35 L/min), and low solution uptake rates (80-110 microL/min) are required to operate the LB-DIHEN at optimum conditions for ICPMS. Detection limits and sensitivities measured with the LB-DIHEN are superior to those of a conventional nebulizer-spray chamber combination, but precision is inferior. The performance of the LB-DIHEN is further explored in the determination of trace elements in an herbal extract.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.